Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jin Bu Huan

This article was originally published in The Tan Sheet

Executive Summary

FDA issues April 15 "Talk Paper" describing the hazards of consuming Jin Bu Huan Anodyne Tablets, an herbal imported from Kwangsi, China. The agency noted that the product has been listed on an FDA import alert with "more than a dozen" other Chinese herbals "known to be harmful due to adulteration and inadequate labeling" and that Jin Bu Huan is currently subject to "automatic import detention by FDA." FDA's Office of Health Affairs recently sent a notification to field offices to be on the look-out for Jin Bu Huan ("The Tan Sheet" April 11, In Brief)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS082683

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel